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Demonstration of hepatic steatosis by computerized
tomography in patients receiving 5-fluorouracil-based
therapy for advanced colorectal cancer
PD Peppercorn1, RH Reznekl, P Wilson2, ML Slevin2 and RK Gupta2
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Summary The frequency and severity of fatty infiltration of the liver in patients receiving 5-fluorouracil (5-FU) and folinic acid has not been
documented systematically. Its development can result in difficulty assessing disease progression, and treatment may be altered
inappropriately. Twenty-seven patients with colon cancer and liver metastases receiving 5-FU and folinic acid were studied with computerized
tomography (CT) before treatment and after six or 12 cycles of chemotherapy. Forty-seven per cent of patients developed hepatic steatosis
during treatment. There was no correlation between development of hepatic steatosis and the dose of chemotherapy or the liver function
tests. Hepatic steatosis occurs commonly in patients receiving 5-FU and folinic acid and can be severe. Its development can make hepatic
metastases difficult to assess and if its benign nature is not appreciated treatment may be inappropriately altered.
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In the treatment of patients with advanced colorectal cancer,
abdominal computerized tomography (CT) is the most widely
used technique to determine stage and to monitor the response of
liver metastases and other sites ofdisease to 5-fluorouracil (5-FU)-
based chemotherapy. The diagnosis of metastatic disease is either
made during laparotomy or by CT- or ultrasound-guided liver
biopsy.
It has been observed, while scanning such patients, that they
may develop a decrease in liver attenuation consistent with
steatosis during treatment with 5-FU, which is used extensively
alone or in combination with other drugs for adenocarcinoma of
the large bowel. Although fatty change of the liver is well recog-
nized after administration of various chemotherapy regimens
(Leevy and Tygstrup, 1976), its frequency and severity has not
been documented. Also its occurrence after 5-FU alone or with
folinic acid has been noted incidentally in one study and found
only to occur when administered with interferon in another
(Moertel et al, 1993; Sorensen et al, 1995). The accuracy ofCT in
establishing the presence of fatty change of the liver is well estab-
lished (Bydder et al, 1980).
The decrease in liver attenuation is important because metas-
tases demonstrated on CT are usually of lower attenuation than
normal liver parenchyma and as the liver becomes more fatty, and
therefore less dense, the metastases can become increasingly diffi-
cult to delineate. This may result in the false impression of a ther-
apeutic response. The confusion can be exacerbated particularly in
the presence of focal sparring within fatty change that can mimic
metastases (Yates and Streight, 1986). Treatment may be stopped
if this benign cause for the liver appearances is misinterpreted as
progressive disease.
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The aim of this study is to examine the frequency and severity
of fatty change of the liver as seen on CT in patients receiving 5-
FU and folinic acid, and to document its relationship to the quan-
tity of chemotherapy and correlate this with biochemical liver
function.
PATIENTS AND METHODS
Twenty-seven patients treated in the period between May 1991
and June 1994 were studied. Thirteen of these were reviewed
retrospectively and 14 patients studied prospectively. One patient
had previously received 5-FU-based adjuvant chemotherapy. All
patients had known liver metastases and suitable pre- and post-
contrast CT examinations available for study, before starting
chemotherapy. Each cycle of chemotherapy consisted of folinic
acid (200 mg m-2, maximum total dose of 350 mg) infusion over
2 h, followed by 5-FU intravenously (800 mg m-2) over 22 h and
then repeated the following day (De Gramont regimen).
Patients with a known cause for fatty liver, such as diabetes
mellitus, malabsorption and pancreatitis were excluded.
Documentation of alcohol history was poor but if the baseline CT
examination did not show fatty infiltration it was assumed that
drinking habits had not changed, or had decreased during treat-
ment, and these patients were included. Patients who had progres-
sive disease defined by increasing size of metastases or rising
tumour markers were also excluded to ensure that the decrease in
liver attenuation was due to infiltration with fat rather than
progressing liver metastases.
All patients had a baseline CT examination ofthe abdomen with
and without intravenous contrast medium and were re-examined
after six or 12 cycles of chemotherapy using the same scanning
protocol. The scans were performed on a GE Hi- speed advantage
machine. Contiguous 10-mm slices were performed before and
during intravenous administration of 100 ml of Omnipaque 300
either by hand injection or by using a pump with a flow rate of
3 ml s-'. This provided eight to ten anatomical sections through the
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liver, both before and after intravenous contrast medium, for each
examination. Liver attenuation was measured on the uncontrasted
images using a 100 mm3 ROI cursor. Three measurements were
made randomly on each image with reference to the contrast
enhanced images to avoid the liver metastases and vessels.
Observations were made by two radiologists independently (DP
and RHR). The median liver attenuation for each image was calcu-
lated and the median ofall the images was taken to give the overall
liver attenuation for each CT examination. If the patient was
scanned several times during treatment the maximum change in
liver attenuation was taken irrespective of when this occurred. A
small number of patients were referred for further CT examina-
tions after completion of chemotherapy, and in these patients liver
attenuation was calculated using the same method. Liver function
tests (AST, alkaline phosphatase and LDH), tumour markers (CEA
and CA19/9) and clinical response were all documented at the time
of each CT examination. Based on the null hypothesis that there
would be no change in liver attenuation after treatment, statistical
analysis was performed using Student's t-test.
RESULTS
From the initial 27 patients, six were excluded. Two patients had a
liver attenuation of 34.8 Hounsfield units (HU) and 38 HU before
treatment, although the cause of their fatty infiltration was not
apparent. Four patients had progressive disease after six cycles of
chemotherapy, as determined by a rising CEA and increasing size
of the liver metastases. The remaining 21 patients (11 male, ten
female, age 37-74 years) were included in the analysis, all of
whom had clinically either a partial response or stable disease at
the time ofrestaging.
All patients had a liver attenuation of >43 HU before treatment
(mean 53.5 HU, range 43.1-62.4) and after completion of
chemotherapy, the mean liver attenuation was 40.3 HU, with a
range between -3.9 and 63.1 HU. The mean fall in liver attenua-
tion was 13.2 HU (Figure 1).
Eleven patients had a change in liver attenuation of less than
10 HU. Five of these had an actual increase in liver attenuation.
The remaining ten patients demonstrated a decrease ofgreater than
10 HU (range 11.9-53.7 HU), of which four patients had a fall of
20-30 HU and two a fall of >50 HU. Overall, there was a signifi-
cant difference in liver attenuation of all 21 patients before and
after treatment (P = 0.0019). There was no statistical difference
between male and female (P = 0.685). Four patients continued to
have CT examinations after completion of chemotherapy, and in
each case there was an increase in liver attenuation (after the initial
decrease) with a mean of 17 HU (range 7-21 HU). These CT
examinations were performed between 3 and 6 months after
finishing treatment.
In all patients the decrease in liver attenuation was diffuse rather
than focal. Although the results of liver function tests (AST and
alkaline phosphatase) fluctuated, the majority of patients (n = 18)
had levels that remained within the normal range throughout treat-
ment. Three patients had AlkP levels above the normal range
during treatment but these returned to normal during treatment,
except in one case when the alkaline phosphatase fell from four
times normal to two times normal; all these patients had a change
in liver attenuation ofless than 10 HU.
The AST was elevated before treatment in three patients but in
all cases returned to normal during treatment; this was seen in two
of these patients who had a change in liver attenuation of less than
10 HU and in one patient who had a decrease of29 HU. Abnormal
liver function tests were not seen in the patients who developed the
greatest decrease in liver attenuation. There was no correlation
between the liver function tests and the degree offatty infiltration.
In 14 patients the maximum decrease in liver attenuation
occurred after the first six cycles of chemotherapy and in six
patients after 12 cycles. One patient had only four cycles of
chemotherapy. The average total dose of5-FU was 19 984 mg and
the median time to develop decrease in liver attenuation was 126
days (range 75-287 days).
DISCUSSION
In this study, 16 out of21 (76%) patients receiving 5-FU and folinic
acid developed a decrease in liver attenuation during treatment and
in 10 out of 21 (48%) this was sufficient to cause steatosis. The
accuracy of unenhanced CT in the diagnosis of fatty infiltration of
the liver is well established (Bydder et al, 1980, 1981; Allaway
et al, 1988). There is a good inverse relationship between the CT
number in Hounsfield units and the triglyceride content of the liver
(Allaway et al, 1988; Bydder et al, 1980). Severe fatty infiltration
when the portal veins become more dense than the surrounding
hepatic parenchyma may be easy to recognize (Scatarige et al,
1984), but less marked changes may be difficult to appreciate and
previous studies have shown that a fall ofjust 10 HU corresponded
to a grade 1 steatosis at biopsy (Sorensen et al, 1995).
In view of the previously established inverse relationship
between fatty change and attenuation value on CT, it was not
considered ethical to biopsy patients for histological confirmation
as this would not have altered management; however the exclusion
of patients who had evidence of progressive disease either on CT,
clinical or biochemical grounds, or elevation of tumour markers
ensured that the decrease in liver attenuation was not due to diffuse
metastatic infiltration. The increase in liver attenuation seen in
those patients scanned after chemotherapy further supports this.
Fatty infiltration can be diffuse (Stephens and Sheedy, 1983), and
both types have been documented in patients receiving
chemotherapy (Gimondo et al, 1995; Sorensen et al, 1995).
Recognition of diffuse fatty infiltration in patients receiving
chemotherapy for a known malignancy is important; initially the
liver is ofhigher attenuation than the hepatic metastases, but as the
liver becomes less dense the metastatic deposits appear isodense
and thus difficult to delineate, making assessment of size and
hence response to treatment difficult.
Secondly, if the benign cause of the liver appearances are not
appreciated, treatment may be inappropriately stopped or altered.
Focal fatty infiltration can produce further confusion (Yates and
Streight, 1986; Gimondo et al, 1995). Commonly focal fatty infil-
tration produces wedge-shaped areas of low attenuation, extending
to the periphery of the liver without mass effect (Halvorsen et al,
1976). This is usually easy to diagnose on ultrasound or CT;
however, in the context of patients receiving chemotherapy,
assessment ofthe presence and size of metastases is more difficult.
Multiple rounded well-defined areas offatty infiltration simulating
metastases have also been described in patients not known to have
malignant disease who were being investigated for abdominal pain
(Yates and Streight, 1986). In both these situations, ifthe diagnosis
is considered, magnetic resonance imaging (MRI) may be more
helpful (Schertz et al, 1989) and may obviate the need for biopsy.
The mechanism of fatty infiltration of the liver is unknown.
Hepatotoxicity has rarely been reported when 5-FU has been
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administered alone. A recent study demonstrated fatty infiltration
in patients receiving 5-FU combined with IFN but not in those
receiving 5-FU alone or in combination with folinic acid
(Sorensen et al, 1995). A previous study primarily examining
hepatotoxicity of 5-FU and folinic acid included 376 patients of
whom 43 had CT scans of the abdomen, in only 3 of the 43
patients was fatty infiltration of the liver documented. Whether
this was present before treatment was not known (Moertel et al,
1993). The lower incidence reported in this study may be because
fatty infiltration was noted incidentally in the small number of
patients who had CT scans but was not routinely documented.
The findings in this study demonstrate that fatty infiltration of
the liver is more common than previously documented and occurs
in patients given 5-FU notjust in combination with IFN (Sorensen
et al, 1995) but also with folinic acid. It can be severe and cause
difficulty in assessing response to treatment. If its benign and
reversible nature is not recognized, there may be unnecessary
intervention or change in the management of such patients.
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